CURIS INC
Close on Oct 19, 2026
- Market cap
- $815.06K
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | During market hours | – | $-1.25 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 19, 2026 | During market hours | $1.10M | $1.23 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | $3.20M | $-0.49 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | $2.70M | $-0.68 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | Before market open | $2.40M | $-1.25 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 28, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | $2.90M | $-1.70 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | Before market open | $2.50M | $-2.03 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 8, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 2, 2023 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 3, 2023 | During market hours | – | – | – |
Press releases
Announcements Curis filed with the SEC
Curis Provides First Quarter 2026 Business Update
Results of operations · EX-99.1 to Form 8-K
Curis Provides Fourth Quarter 2025 Business Update
Results of operations · EX-99.1 to Form 8-K
Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Curis Provides Third Quarter 2025 Business Update
Agreement terminated · Acquisition or disposition completed · Results of operations · Other events · EX-99.1 to Form 8-K
Curis Provides Second Quarter 2025 Business Update
Results of operations · EX-99.1 to Form 8-K
Corporate Presentation July 2025 Exhibit 99.1
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Curis Announces $7.0 Million Registered Direct and Concurrent Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Curis Provides First Quarter 2025 Business Update
Results of operations · EX-99.1 to Form 8-K
Curis Provides Fourth Quarter 2024 Business Update
Results of operations · EX-99.1 to Form 8-K
Unaudited Condensed Consolidated Balance Sheets
Material agreement · Results of operations · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Curis Provides Third Quarter 2024 Business Update
Results of operations · EX-99.1 to Form 8-K
Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Curis Provides Second Quarter 2024 Financial and Operating Update
Results of operations · EX-99.1 to Form 8-K
mean the Board or a Committee of the Board or the officers referred to in Section 3(c) to the extent that the Board’s powers or authority under the Plan have been delegated to such Committee or officers.
Executive or director change · Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.1 to Form 8-K
AMENDED AND RESTATED 2010 EMPLOYEE STOCK PURCHASE PLAN
Executive or director change · Charter or bylaw amendment · Shareholder vote results · Other events · EX-99.2 to Form 8-K
Curis Announces Additional Data from TakeAim Leukemia Study
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Curis Provides First Quarter 2024 Business Update
Results of operations · EX-99.1 to Form 8-K
Curis Provides Fourth Quarter 2023 Business Update
Results of operations · EX-99.1 to Form 8-K
End of Corporate Presentation NASDAQ: CRIS
Regulation FD disclosure · EX-99.1 to Form 8-K
Curis Provides Third Quarter 2023 Business Update
Results of operations · EX-99.1 to Form 8-K
Curis Provides Second Quarter 2023 Business Update
Results of operations · EX-99.1 to Form 8-K
Curis Announces $15.1 Million Registered Direct Offering
Material agreement · Other events · EX-99.1 to Form 8-K
FDA Removes Partial Clinical Hold on TakeAim Leukemia Study
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Corporate Presentation NASDAQ: CRIS © 2023 Curis, Inc. EXHIBIT 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Curis Provides First Quarter 2023 Business Update
Results of operations · EX-99.1 to Form 8-K
Curis Provides Fourth Quarter 2022 Business Update
Results of operations · Charter or bylaw amendment · EX-99.1 to Form 8-K
Curis Provides Third Quarter 2022 Business Update
Results of operations · EX-99.1 to Form 8-K
FDA Allows Patient Enrollment to Resume in Monotherapy Dose
Other events · EX-99.1 to Form 8-K
FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib
Other events · EX-99.1 to Form 8-K
Curis Reports Second Quarter 2022 Financial Results and Business Update
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Curis Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Curis Announces FDA Partial Clinical Hold for TakeAim Lymphoma Study of Emavusertib (CA-4948)
Other events · EX-99.1 to Form 8-K
Curis Announces FDA Partial Clinical Hold for TakeAim Leukemia Study of Emavusertib (CA-4948)
Other events · EX-99.1 to Form 8-K
Curis Reports Fourth Quarter and Year End 2021
Results of operations · EX-99.1 to Form 8-K
CA-4948 & CI-8993 Clinical Data
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Curis Announces Updated Data with Additional Encouraging Clinical Activity in Phase 1/2 Study of
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Curis Appoints John A. Hohneker, M.D. to Board of Directors
Executive or director change · Other events · EX-99.1 to Form 8-K
Curis Reports Third Quarter 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K